Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/108791
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

G1/S cell cycle checkpoint dysfunction in lymphoblasts from sporadic Parkinson’s disease patients.

AutorEsteras, Noemí CSIC ORCID; Alquézar, Carolina CSIC ORCID; Bartolomé Robledo, Fernando CSIC ORCID; De la Encarnación, Ana CSIC ORCID; Bermejo-Pareja, Félix; Molina, J.A.; Martín-Requero, Ángeles CSIC ORCID
Palabras claveParkinson disease
Lymphocytes
Cell cycle
pRb
CDK6
TDP-43
Cyclin D3
Rapamycin
Sodium butyrate
PD-332991
Fecha de publicación3-sep-2014
EditorHumana Press
CitaciónMolecular Neurobiology, 2014
ResumenParkinson’s disease (PD) is the second most prevalent neurodegenerative disease among aging individuals, affecting greatly the quality of their life. However, the pathogenesis of Parkinson's disease is still incompletely understood to date. Increasing experimental evidence suggests that cell cycle reentry of postmitotic neurons precedes many instances of neuronal death. Since cell cycle dysfunction is not restricted to neurons, we investigated this issue in peripheral cells from patients suffering from sporadic PD and age-matched control individuals. Here, we describe increased cell cycle activity in immortalized lymphocytes from PD patients, that is associated to enhanced activity of the cyclin D3/CDK6 complex, resulting in higher phosphorylation of the pRb family protein and thus, in a G1/S regulatory failure. Decreased degradation of cyclin D3, together with increased p21 degradation, as well as elevated levels of CDK6 mRNA and protein were found in PD lymphoblasts. Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and rapamycin were able to restore the response of PD cells to serum stimulation. We conclude that lymphoblasts from PD patients are a suitable model to investigate cell biochemical aspects of this disease. It is suggested that cyclin D3/CDK6-associated kinase activity could be potentially a novel therapeutic target for the treatment of PD.
Descripción38 p.-8 fig.
Versión del editorhttp://dx.doi.org/10.1007/s12035-014-8870-y
URIhttp://hdl.handle.net/10261/108791
DOI10.1007/s12035-014-8870-y
ISSN0893-7648
E-ISSN1559-1182
Aparece en las colecciones: (CIB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
MOLN 2014, Martín-Requero.pdf2 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

15
checked on 25-mar-2024

WEB OF SCIENCETM
Citations

15
checked on 25-feb-2024

Page view(s)

516
checked on 28-mar-2024

Download(s)

557
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.